BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17661735)

  • 1. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
    Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure.
    Del Sindaco D; Tinti MD; Monzo L; Pulignano G
    Clin Interv Aging; 2010 Dec; 5():381-93. PubMed ID: 21152240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebivolol: a review.
    Cockcroft J
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J
    Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension].
    MMW Fortschr Med; 2003 Oct; 145(40):57. PubMed ID: 14603611
    [No Abstract]   [Full Text] [Related]  

  • 14. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
    Kuroedov A; Cosentino F; Lüscher TF
    Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol for the treatment of heart failure.
    Riva N; Lip GY
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1733-46. PubMed ID: 21980961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebivolol: a new antihypertensive agent.
    Gray CL; Ndefo UA
    Am J Health Syst Pharm; 2008 Jun; 65(12):1125-33. PubMed ID: 18541682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.